Dushon Riley, PhD


View Dushon Riley's profile on LinkedIn

Dushon is a Consultant with BSP whose engagements have spanned the firm’s Health Economics, Medical Communications, and Business and Clinical Strategy practices. His recent work includes:

Health Economics:

  • Evaluated cost drivers and clinical outcomes based on primary and secondary research of hospital-acquired pressure injury development in the acute care setting to inform the business case and market penetration strategies for a medical device company’s alternating pressure support surface
  • Demonstrated the economic impact of adoption of a medical device company’s pressure injury prevention surface through extensive literature review, budget impact model development, and creation of a customer-facing Windows 10 application
  • Developed an abstract and poster for an international meeting showcasing the cost-effectiveness of adoption of a pharmaceutical company’s novel extended-release intra-articular corticosteroid on pain relief in patients with osteoarthritis of the knee

Medical Communications:

  • Identified key medical and trade journals to inform a publication strategy for a medical device company’s multiple assets in the pressure injury prevention space
  • Developed an abstract supporting the safety and efficacy of a client’s proprietary postpartum depression treatment

Business and Clinical Strategy:

  • Performed gap analysis of a client’s current clinical programs, and proposed future clinical trial design to support publication strategy and enable market penetration of a novel pressure injury support surface
  • Assessed market segmentation and opportunity, novel technology adoption likelihood, regulatory and reimbursement landscapes, and other macroeconomic factors to inform the development and launch strategies for a medical device company’s international expansion

Dushon completed his PhD at the University of Maryland School of Medicine where he evaluated the molecular effects of stress events on cardiac physiology and the effects of hyperglycemia on calcium cycling and reactive oxygen species handling. His postdoctoral work focused on developing an early stage model of acute hyperglycemia. He most recently completed a fellowship with the US Food and Drug Administration at the Center for Drug Evaluation and Research (CDER) where he conducted retrospective budget analysis and developed a novel intramural research funding paradigm. Dushon is passionate about traveling, strength training, and supporting STEM education.